Sandoz

Sandoz operates through Sandoz Private Limited (active). Its filings, financials, charges and directors are on the company page.

3 investors in total: 3 institutional.

Sandoz has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Mile High Labs, European Union and PL Developments.

All

Institutional

Investor	Description	Founded Year	Domain	Location
European Union	Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability	1958	europa.eu	Brussels, Belgium
Mile High Labs	Licensed CBD products are manufactured for private labels.	2016	milehighlabs.com	Loveland, United States
PL Developments	Over-the-counter pharmaceuticals and consumer healthcare products are manufactured and distributed.	1988	pldevelopments.com	Westbury, United Kingdom

Premium access

Investor details for Sandoz

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

• Complete investor list
• Round participation
• Investor portfolios
• Co-investor network

Access investors

Verified entity values are shown only after access is granted.

Sandoz Private Limited is the primary company behind Sandoz. The board of Sandoz Private Limited currently have 4 directors; the longest-serving is Sudhir Trambakrao Bhandare, appointed in 2018. 26 earlier directors have ceased.

751 people are tracked at Sandoz (367 in leadership, 7 in board & advisors, 377 in team); the tracked headcount is 23,000.

731 more people are available in the full profile.

Figures of Sandoz Private Limited, the primary company behind Sandoz, for FY 2025. Revenue was ₹2,778 Cr (-2% year on year). Net profit was ₹162 Cr (6% margin). EBITDA was ₹406 Cr (15% margin). Revenue has grown at a compounded annual rate of +18% over three years and +13% over five years.

• ₹2,778 CrRevenue · FY 2025 · -2% YoY
• ₹162 CrNet profit · 6% margin
• ₹406 CrEBITDA · 15% margin
• ₹3.20 CrPaid-up capital
• 1,661Employees (provident fund records)
• +18%Revenue CAGR, 3 years
• +13%Revenue CAGR, 5 years

Balance sheet, profit and loss, cash flow and ratios of Sandoz Private Limited are on its company page.

Sandoz has strategically engaged in corporate development activities, having acquired 6 companies. Notable acquisitions include AmLactin, Aspenpharma and CIMERLI.

11 dated milestones of Sandoz across 138 years, from founding to its latest funding, stage changes and deals.

1. 1886 Founded Sandoz is founded.
2. Apr 2010 Acquisition Acquires Oriel Therapeutics.
3. May 2012 Acquisition Acquires Fougera Pharmaceuticals.
4. Jan 2015 Funding First funding round of $452K.
5. Dec 2016 Acquisition Acquires AmLactin.
6. Dec 2017 Exit Acquired by PL Developments.
7. Jun 2019 Exit Acquired by Mile High Labs.
8. Jan 2020 Acquisition Acquires Aspenpharma.
9. Mar 2022 Acquisition Acquires Coalesce.
10. Oct 2023 IPO Lists on the stock exchange (IPO).
11. Jan 2024 Acquisition Acquires CIMERLI.

The website of Sandoz (sandoz.com) receives about 195.3K visits a month and ranks #232,061 among all websites worldwide, #7,702 in Biotechnology and Pharmaceuticals.

• Monthly visits
  195.3K

  ▲ 9.3% vs previous month

• Unique visitors
  78.5K

  per month

• Global rank
  #232,061

  among all websites

• Category rank
  #7,702

  Health · Biotechnology and Pharmaceuticals

Websites whose visitors overlap most with Sandoz. Affinity shows how closely the audiences match.

Website	Domain	Audience affinity	Monthly visits	Global rank	Profile
Novartis	novartis.com	100%	948.8K	#58,822	View details
sandozfarma.es	sandozfarma.es	93%		#7,476,540	–
Ohara Pharmaceutical	ohara-ch.co.jp	85%		#855,374	View details
nc-medical.com	nc-medical.com	83%		#1,412,918	–
1apharma.de	1apharma.de	82%		#3,139,788	–
••••••••••	••••••.com	••%	•.•M	#•••••	–
••••••••••	••••••.com	••%	•.•M	#•••••	–
••••••••••	••••••.com	••%	•.•M	#•••••	–